Table 3, Results of CDR Multi-way Analysis Using Health State Utility From CDR Models - Ustekinumab (Stelara)

Warning: The NCBI web site requires JavaScript to function. more...

Table 3Results of CDR Multi-way Analysis Using Health State Utility From CDR Models

	ICUR ($/QALY)
	Versus Conventional Therapy	Sequential Analysis
Population experiencing FCTO
Ustekinumab q.12.w.	$115,474	$115,474
Ustekinumab mixed q.8.w./q.12.w.	$147,517	$623,571
Ustekinumab mixed q.8.w.	$169,543	$658,533
Biosimilar infliximab q.8.w.	$143,062	Subject to extended dominance^a
Adalimumab q.2.w.	$164,583	Subject to extended dominance^b
Vedolizumab q.8.w.	$271,363	Dominated by adalimumab q.2.w.
Infliximab q.8.w.	$342,856	Dominated by biosimilar infliximab q.8.w., vedolizumab q.8.w., adalimumab q.2.w.
Population experiencing failure with anti-TNF therapy
Biosimilar infliximab q.8.w.	$90,277	$90,277
Ustekinumab q.12.w.	$131,297	$228,571
Ustekinumab mixed q.8.w./q.12.w.	$189,403	$1,332,167
Ustekinumab q.8.w.	$203,880	$1,999,000
Adalimumab q.2.w.	$134,373	Dominated by biosimilar infliximab q.8.w.
Infliximab q.8.w.	$284,904	Dominated by adalimumab q.2.w., biosimilar infliximab q.8.w., ustekinumab q.12.w., ustekinumab mixed
Vedolizumab q.8.w.	$500,920	Dominated by adalimumab q.2.w., biosimilar infliximab q.8.w.
IM-UNITI (mixed) population
Ustekinumab q.12.w.	$119,058	$119,058
Ustekinumab q.8.w.	$177,093	$744,826
Biosimilar infliximab q.8.w.	$120,923	Subject to extended dominance^c
Adalimumab q.2.w.	$154,194	Subject to extended dominance^d
Ustekinumab mixed q.8.w./q.12.w.	$157,268	Subject to extended dominance^e
Vedolizumab q.8.w.	$311,328	Dominated by biosimilar infliximab q.8.w., adalimumab q.2.w.
Infliximab q.8.w.	$317,945	Dominated by biosimilar infliximab q.8.w., adalimumab q.2.w., ustekinumab q.12.w.

: FCTO = failure with conventional therapy only; ICUR = incremental cost-utility ratio; QALY = quality-adjusted life-years; q.2.w. = every 2 weeks; q.8.w. = every 8 weeks; q.12.w. = every 12 weeks; TNF = tumour necrosis factor.
a: Subject to extended dominance through conventional therapy and ustekinumab q.12.w.
b: Subject to extended dominance through conventional therapy and ustekinumab q.12.w., biosimilar infliximab q.8.w. and ustekinumab q.12.w., conventional therapy and ustekinumab mixed, biosimilar infliximab q.8.w. and ustekinumab mixed, biosimilar infliximab q.8.w. and ustekinumab q.8.w.
c: Subject to extended dominance through conventional therapy and ustekinumab q.12.w.
d: Subject to extended dominance through conventional therapy and ustekinumab q.12.w., biosimilar infliximab q.8.w. and ustekinumab q.12.w., biosimilar infliximab q.8.w. and ustekinumab mixed, biosimilar infliximab q.8.w. and ustekinumab q.8.w.
e: Subject to extended dominance through ustekinumab q.12.w. and ustekinumab q.8.w.

From: 5, CADTH COMMON DRUG REVIEW REANALYSES

Ustekinumab (Stelara) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.